Sandra Rebouissou, Andrea Franconi, Julien Calderaro, Eric Letouzé, Sandrine Imbeaud, Camilla Pilati, Jean‐Charles Nault, Gabrielle Couchy, Alexis Laurent, Charles Balabaud, Paulette Bioulac‐Sage, Jessica Zucman‐Rossi – 14 May 2016 – CTNNB1 mutations activating ß‐catenin are frequent somatic events in hepatocellular carcinoma (HCC) and adenoma (HCA), particularly associated with a risk of malignant transformation. We aimed to understand the relationship between CTNNB1 mutation types, tumor phenotype, and level of ß‐catenin activation in malignant transformation.

Lee J. Hewett, Marques L. Bradshaw, Leonie L. Gordon, Don C. Rockey – 14 May 2016

Heekyong R. Bae, Patrick S.C. Leung, Koichi Tsuneyama, Julio C. Valencia, Deborah L. Hodge, Seohyun Kim, Tim Back, Megan Karwan, Anand S. Merchant, Nobuyuki Baba, Dechun Feng, Ogyi Park, Bin Gao, Guo‐Xiang Yang, M. Eric Gershwin, Howard A. Young – 14 May 2016 – In most autoimmune diseases the serologic hallmarks of disease precede clinical pathology by years. Therefore, the use of animal models in defining early disease events becomes critical.

Jonas Schreiber, John McNally, Krishna Chodavarapu, Evguenia Svarovskaia, Christophe Moreno – 14 May 2016 – During a phase 3 study evaluating the combination of sofosbuvir‐velpatasvir for 12 weeks in patients with genotype 1, 2, 4, 5, and 6 hepatitis C virus (HCV) infection, we enrolled a patient who was subsequently found to be infected with genotype 7 HCV. This patient tolerated the study regimen well and achieved sustained virological response 12 weeks after treatment (SVR12). (Hepatology 2016;64:983‐985)

Jonas Schreiber, John McNally, Krishna Chodavarapu, Evguenia Svarovskaia, Christophe Moreno – 14 May 2016 – During a phase 3 study evaluating the combination of sofosbuvir‐velpatasvir for 12 weeks in patients with genotype 1, 2, 4, 5, and 6 hepatitis C virus (HCV) infection, we enrolled a patient who was subsequently found to be infected with genotype 7 HCV. This patient tolerated the study regimen well and achieved sustained virological response 12 weeks after treatment (SVR12). (Hepatology 2016;64:983‐985)

Viju Kumar Bharathan, Biju Chandran, Unnikrishnan Gopalakrishnan, Christi Titus Varghese, Ramachandran N. Menon, Dinesh Balakrishnan, O. V. Sudheer, Puneet Dhar, Sudhindran Surendran – 6 May 2016 – The role of prostaglandin E1 (PGE1) infusion in improving early graft function has not been well defined, especially in the scenario of living donor liver transplantation (LDLT). We designed a randomized, double‐blind, placebo‐controlled trial to evaluate the role of perioperative PGE1 infusion in LDLT.

Dmitry Tumin, Don Hayes, W. Kenneth Washburn, Joseph D. Tobias, Sylvester M. Black – 6 May 2016 – Liver transplantation (LT) recipients in the United States have low rates of paid employment, making some eligible for Medicaid public health insurance after transplant. We test whether recent expansions of Medicaid eligibility increased Medicaid enrollment and insurance coverage in this population.

Michael Osseis, Chetana Lim, Chady Salloum, Georges Boustany, Alexandre Doussot, Eylon Lahat, Concepcion Gomez Gavara, Philippe Compagnon, Alain Luciani, Daniel Azoulay – 5 May 2016

Fabrizio Panaro, Gildas Boisset, Gérald Chanques, Boris Guiu, Astrid Herrero, Hassan Bouyabrine, Georges Philippe Pageaux, Karim Boudjema, Francis Navarro – 5 May 2016 – Recipient hepatectomy is a challenging liver transplantation (LT) procedure that has life‐threatening complications. The current predictive mortality clinic‐biological scores (Child/Model for End‐Stage Liver Disease [MELD]) do not take into consideration the recipient's liver anatomy.

Patricia Jones, Fasiha Kanwal – 5 May 2016